The second annual Peehavior survey conducted by Astellas Pharma and Ipsos Public Affairs found that many women who have symptoms of overactive bladder (OAB) have used unconventional methods when they have not had easy access to a restroom.
Pharmaceutical company Astellas Pharma has been named a Best Place to Work for lesbian, gay, bisexual and transgender equality as it obtained a perfect score on the Human Rights Campaign Foundation’s (HRC) Corporate Equality Index (CEI).
The U.S. Food and Drug Administration (FDA) recently granted fast track designation to Astellas Pharma to develop gilteritinib, an investigational compound, for patients with FLT3 mutation-positive (FLT3+) relapsed or refractory acute myeloid leukemia (AML).
Astellas Pharma, and Seattle Genetics recently began dosing the first patient in a registrational, phase two clinical trial of enfortumab vedotin for patients with certain forms of urothelial bladder cancer.
Astellas said preliminary results from an ongoing clinical trial of its potential leukemia drug gilteritinib show it may be a long-awaited treatment option for certain patients with a acute myeloid leukemia.
An amendment to an international Phase 3 clinical trial for prostate cancer drug Xtandi (enzalutamide) will cut the sample size by 120 subjects and provide results later this year, nearly two years ahead of schedule.
Astellas recently launched its strategic initiative for building sustainable communities, called the new Social Responsibility platform of Living SMART, in addition to its Americas Corporate Social Responsibility (CSR) Report Card 2015.
Astellas, a pharmaceutical company that specializes in improving people’s health across the globe, recently announced that its representatives had presented abstracts including early phase data at the 2016 American Society of Clinical Oncology annual meeting.
Astellas Pharma Inc. and Medivation Inc. recently announced that it will initiate its new phase-three clinical trial to evaluate the safety and efficacy of enzalutamide for treating patients who have triple-negative breast cancer (TNBC).
DiversityComm Inc. recently listed Astellas as a leading employer in the pharmaceutical, health care and biotech industry, and 'Professional Woman’s Magazine' named Astellas a 'Best of the Best' employer.
Astellas recently announced that it has chosen Rodrigo Fernandez as its new executive director of international business, where Fernandez will lead the company's business operations across Latin America, excluding Brazil.